Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Beta Bionics, Inc. (BBNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, toda
How this was made
The 30-second read
Why it matters
The updated guidance and cash position may attract short‑term buying, but execution of FDA clearances remains a key risk.
Market read
Earnings release with guidance update provides fresh data for traders; modest upside potential balanced by regulatory execution risk.
What to watch
Potential revenue deferral of up to $8.5 million in Q4 could temper upside.
Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Net sales grew 30% and gross margin expanded, led by PBP channel growth, but operating and net losses widened and full-year revenue guidance now incorporates a potential fourth-quarter revenue deferral impact.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $35.51M | – | up 30% |
| Net sales, nine months ended September 30, 2026GAAP | $95.14M | – | – |
| Cost of sales, three months ended September 30, 2026GAAP | 15,174 | – | – |
| Cost of sales, nine months ended September 30, 2026GAAP | 39,474 | – | – |
| Gross profit, three months ended September 30, 2026GAAP | 20,331 | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | 55,670 | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 57.3 % | – | up 179 basis points |
| Gross margin, nine months ended September 30, 2026GAAP | 58.5 % | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | 11,975 | – | – |
| Research and development expense, nine months ended September 30, 2026GAAP | 32,571 | – | – |
| Sales and marketing expense, three months ended September 30, 2026GAAP | 25,124 | – | – |
| Sales and marketing expense, nine months ended September 30, 2026GAAP | 70,499 | – | – |
| General and administrative expense, three months ended September 30, 2026GAAP | 9,841 | – | – |
| General and administrative expense, nine months ended September 30, 2026GAAP | 29,058 | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | 46,940 | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | 132,128 | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$26.61M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$76.46M | – | – |
| Interest income, three months ended September 30, 2026GAAP | 2,258 | – | – |
| Interest income, nine months ended September 30, 2026GAAP | 6,811 | – | – |
| Other (expense) income, net, three months ended September 30, 2026GAAP | (2 ) | – | – |
| Other (expense) income, net, nine months ended September 30, 2026GAAP | (4 ) | – | – |
| Change in fair value of warrant liabilities, three months ended September 30, 2026GAAP | — | – | – |
| Change in fair value of warrant liabilities, nine months ended September 30, 2026GAAP | — | – | – |
| Total other income (expense), net, three months ended September 30, 2026GAAP | 2,256 | – | – |
| Total other income (expense), net, nine months ended September 30, 2026GAAP | 6,807 | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$24.35M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$69.65M | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$24.84M | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$70.93M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | $ (0.52 ) | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP | $ (1.54 ) | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 46,541,997 | – | – |
| Weighted-average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 45,224,038 | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | −$18.91M | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | −$54.28M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| DME channel, three months ended September 30, 2026iLet revenue was $ 11,563 and single-use products revenue was 10,334. | $21.90M | – | up 4% |
| PBP channel, three months ended September 30, 2026iLet revenue was (37 ) and single-use products revenue was 13,645. | $13.61M | – | up 118% |
| DME channel, nine months ended September 30, 2026iLet revenue was 34,303 and single-use products revenue was 24,930. | 59.23M | – | – |
| PBP channel, nine months ended September 30, 2026iLet revenue was 649 and single-use products revenue was 35,262. | 35.91M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full year 2026 outlook
- Revenueapproximately $124 million to $126 million
- Gross margin58.5% to 59.5%
- NoteEstimated 37% to 39% of new patient starts reimbursed through the PBP channel.
- NoteRevenue guidance reflects a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint.
- NoteDuring the full year 2027, the Company expects Mint to recapture any revenue lost in the fourth quarter of 2026.
What drove it
- Net sales of $35.5 million were up 30% compared to $27.3 million in the third quarter of 2025.
- PBP channel net sales of $13.6 million were up 118% compared to $6.2 million in the third quarter of 2025.
- Gross margin was 57.3%, up 179 basis points compared to 55.5% in the third quarter of 2025.
- New patient starts increased by a mid-single digit percentage versus the second quarter of 2026.
- 69% of new patient starts came from multiple daily injections (MDI).
- High 30s percentage of new patient starts reimbursed through the PBP channel.
- Announced FDA clearance of Mint™ and expectations for full U.S. commercial launch of Mint in the first quarter of 2027.
- Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026.
Concerns
- Loss from operations was $26.6 million, or negative 75% of sales, compared to $17.0 million or negative 63% of sales in the third quarter of 2025.
- Net loss was $24.4 million, or negative 69% of sales, compared to $14.2 million or negative 52% of sales in the third quarter of 2025.
- Adjusted EBITDA was negative $18.9 million, or negative 53% of sales, compared to negative $12.2 million or negative 45% of sales in the third quarter of 2025.
- The Company withdrew its 510(k) application for 3D Intelligence following recent interactions with the FDA and intends to submit a revised 510(k) in mid-Q4 2026.
- Full-year revenue guidance reflects a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026 as prospective iLet users could await Mint.
What to watch
- Submission of the revised 510(k) for 3D Intelligence in mid-Q4 2026.
- Potential commercialization of iLet 3D™ and Mint 3D™ in the first half of 2027, with potential for an earlier fourth-quarter 2026 launch subject to FDA clearance.
- Full U.S. commercial launch of Mint in the first quarter of 2027 and anticipated manufacturing capacity to produce at least 1.5 million total disposable units in the full year 2027.
- Commercial launch of the integrated iLet and Eversense 365 system expected in the fourth quarter of 2026.
- Initiation of a pivotal trial for the next-generation fully-closed loop algorithm in the fourth quarter of 2026.
- Expected expansion of iLet's indications for use to adults with type 2 diabetes around mid-year 2027, subject to regulatory clearance by the FDA.
Balance sheet and cash flow
- Cash and cash equivalents of $ 81,551 as of September 30, 2026, compared to $ 31,576 at December 31, 2025.
- Short-term investments of 158,653 as of September 30, 2026, compared to 187,549 at December 31, 2025.
- Long-term investments of 133,436 as of September 30, 2026, compared to 45,431 at December 31, 2025.
- Cash, cash equivalents, short and long-term investments of $373.6 million as of September 30, 2026.
- Accounts receivable, net of 20,667 as of September 30, 2026, compared to 17,118 at December 31, 2025.
- Inventories, net of 22,971 as of September 30, 2026, compared to 21,722 at December 31, 2025.
- Total assets of $ 443,759 as of September 30, 2026, compared to $ 328,743 at December 31, 2025.
- Total current liabilities of 32,836 as of September 30, 2026, compared to 30,924 at December 31, 2025.
- Total liabilities of 42,376 as of September 30, 2026, compared to 41,133 at December 31, 2025.
- Total stockholders' equity of 401,383 as of September 30, 2026, compared to 287,610 at December 31, 2025.
- Completed public offering of common stock, raising approximately $161.3 million in net proceeds to the Company.
Analysis
Third-quarter net sales reached $35.5 million, up 30% from $27.3 million in the third quarter of 2025. Growth was led by the PBP channel, where net sales rose 118% to $13.6 million, while DME channel net sales increased 4% to $21.9 million. New patient starts increased by a mid-single digit percentage versus the second quarter of 2026, 69% of new patient starts came from MDI, and a high 30s percentage were reimbursed through the PBP channel.
Mix and execution supported gross margin expansion. Gross margin was 57.3%, up 179 basis points from 55.5% in the third quarter of 2025. The PBP channel's single-use products revenue was 13,645 in the quarterly channel table, while DME single-use products revenue was 10,334. Nine-month gross margin was 58.5%, compared with 53.7% in the prior-year period.
Profitability remained under pressure as commercial and development spending increased. Sales and marketing expense was 25,124 versus 16,045, research and development expense was 11,975 versus 8,195, and total operating expenses were 46,940 versus 32,162. Loss from operations was $26.6 million and net loss was $24.4 million. Adjusted EBITDA was negative $18.9 million, compared with negative $12.2 million in the third quarter of 2025.
The balance sheet was strengthened by a public offering that raised approximately $161.3 million in net proceeds. The company reported $373.6 million in cash, cash equivalents, short and long-term investments as of September 30, 2026. Full-year revenue guidance was updated to approximately $124 million to $126 million from previously $121 million to $126 million, while PBP reimbursement and gross-margin guidance were unchanged. The outlook explicitly includes a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026 as users may await Mint.
Product and regulatory milestones are central to the next period. Mint received FDA clearance, with full U.S. commercial launch expected in the first quarter of 2027. The company withdrew its 510(k) application for 3D Intelligence and plans to submit a revised application in mid-Q4 2026 with additional simulator validation data. Management expects to commercialize iLet 3D and Mint 3D in the first half of 2027, subject to FDA clearance, while the integrated iLet and Eversense 365 system is expected to launch in the fourth quarter of 2026.
Not in the filing
stated, not guessed- Prior-release outlook section was not provided; therefore, actual results were not assessed against prior guidance in vs_prior_guidance.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt was not reported.
- Capital returns, including share repurchases and dividends, were not reported.
- No named executive quotations were provided.
- No prior-quarter figures were reported for the financial-statement metrics.
- No full-year 2026 operating-expense or tax-rate guidance was reported.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Beta Bionics is a Nasdaq‑listed developer of advanced insulin‑delivery systems.
Ticker impact
Beta Bionics reported Q3 2026 results and updated full‑year 2026 revenue guidance to $124‑$126 million.
likely modest upside as the market prices in the higher revenue range
The company updated its top‑line guidance and disclosed a cash balance of $373.6 million, reducing downside risk and suggesting stronger liquidity.
Market effects
May boost sentiment for med‑tech and diabetes‑device peers.
Limited to U.S. biotech investors.
Minimal global impact beyond niche healthcare sector.
Counterpoint
Guidance increase is modest; execution risk remains high given ongoing FDA reviews.
Key entities
- companyBeta Bionics, Inc.
Medical device maker reporting Q3 results and guidance.
